Greggs shares: it can’t go on like this, can it?
I donât know what inspired the Mick McCarthy reference in the title, but sadly, Iâm not very optimistic about Greggs (LSE:GRG) shares. And while I feel for the company and everyone who may benefit from an elevated share price, itâs great to see the stock return to more manageable valuation multiples. On a forward basis, […]
We Need to Quickly Find Out If GLP-1s Help With Addiction
Early research on using GLP-1 drugs as an addiction treatment is promising, as are the anecdotes we hear. But formal clinical data is limited, and in an opinion piece for the New York Times , Maia Szalavitz argues that needs to change—fast. “Unlike new drug compounds that take years to…
Novo Nordisk GLP-1 pill now U.S. approved for heart disease risk
This Stellar Vanguard ETF Is Beating the VTI and VOO This Year
Key Points The VOO and VTI are exceptional Vanguard ETFs, but the VGK is a worthy complement, especially for investors who want more of a value tilt. Diversifying internationally may be viewed as overrated for some. But amid climbing multiples in U.S. stocks, I think the case for expanding internationally is strengthening. It’s cheap to […]
Abbott: GLP-1 Beneficiary – A Dividend Raise May Be Coming
Surgery beats Ozempic for long-term health, Cleveland Clinic finds
Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.
Prevent Muscle Loss During GLP-1 and Rapid Weight Loss
Trump says Ozempic prices will be ‘much lower’ for Americans – Fox Business
Trump says Ozempic prices will be ‘much lower’ for Americans Fox Business Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs The Wall Street Journal Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s CNBC GLP-1 stocks wilt following Trump comments Axios Trump’s Ozempic comment that sent weight […]
GLP‐1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study
Abstract Aims Evidence on the safety of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RA) concerning non-arteritic anterior ischemic optic neuropathy (NAION) is inconclusive, with several studies published to date presenting methodological challenges. We sought to compare the risk of presumed NAION in patients with type 2 diabetes (T2D), initiating a GLP-1RA versus a sodium-glucose […]
Effects of GLP‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized controlled trials
Abstract Aims Patients with type 2 diabetes mellitus (T2DM) have a significantly increased risk of cognitive impairment, and the protective effects of traditional hypoglycaemic drugs on cognitive function remain unclear. This study systematically evaluated the neuroprotective effects of GLP-1 receptor agonists (GLP-1RAs) based on randomized controlled trial (RCT) evidence, aiming to provide key evidence-based insights […]